M6P Therapeutics

Coming – July 23

One Platform. Fifty Targets. Fifteen Programs.

Date and Time

July 23

11:00 AM ET / 8:00 AM PT

Location will be provided upon RSVP approval

About this Event

M6P Therapeutics has deep expertise on lysosomes, which are the compartments within each cell that break down and recycle materials. Their expertise has lead to unparalleled ability to create more effective therapies for individuals affected by lysosomal storage disorders (LSDs). Among the 50 known LSDs – which includes Pompe, Gaucher, and Fabry disease – there are no known cures and just a few treatments with limited effectiveness.

The company’s S1S3 platform is a breakthrough technology that unlocks the potential of mannose 6-phosphate, driving the development of next generation enzyme replacement and gene therapies. M6P currently has 15 programs in place leveraging the power of this platform, six of which have received Rare Pediatric Drug designation from the FDA. Each of these designations comes with a voucher worth at least $100M when the drug is launched. With the ability to cross the blood brain barrier, this technology also has the potential to treat a subgroup of Parkinson’s disease known as GBA-linked Parkinson’s. The company has 5 programs that can be in the clinic over the next 18 months and over 50 patents protecting their technology.

Please join us along with M6P Founder and CEO, Cuong Do, and Chief Science Officer, Hung Do, as they discuss the science behind the technology and their platform’s potential to reach blockbuster status.

Hosted by Force Family Office CEO, Steven Saltzstein

Sign Up Today


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.